All In Biotech

Drug Trial Radar · NCT05059509

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

An Open Labeled Exploratory Study to Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 6, 2020

Primary completion

May 10, 2021

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Oneness Biotech Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open labeled exploratory study to evaluate efficacy of FB825 in adults with atopic dermatitis (AD). The study will be conduct at one medical center in Taiwan. Approximately 20 subjects with atopic dermatitis (AD), who meet the criteria for study entry, will be enrolled to the study. All eligible subjects will receive FB825, 5mg/kg, by 1 hour IV infusion on Day 1. Subjects will return to the study site on Days 15, 29 and 57 for the safety and efficacy evaluation. Subjects who premature withdraw from the study will have an end of study (EOS) visit within 7 days.

Conditions

  • Atopic Dermatitis

Interventions

  • FB825Biological

    FB825, 5mg/kg, by 1 hour IV infusion on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean change in mIgE (Membrane bound Immunoglobulin E) B cell count (absolute and percentage) from baselineTime frame: week 2 and 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.